Johnson & Johnson (JNJ) – Company Press Releases
-
Biosense Webster Submits Application to U.S. FDA Seeking Approval of the VARIPULSE™ Platform for the Treatment of Paroxysmal Atrial Fibrillation
-
Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge
-
Johnson & Johnson to Host Investor Conference Call on First-Quarter Results
-
Johnson & Johnson Completes Acquisition of Ambrx
-
RYBREVANT® (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutat
-
TECVAYLI® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma
-
Johnson & Johnson to Participate in the Barclays 26th Annual Global Healthcare Conference
-
Johnson & Johnson to Participate in the Leerink Global Biopharma Conference
-
Biosense Webster Presents Late-Breaking Data from inspIRE and admIRE Clinical Trials at AF Symposium
-
Johnson & Johnson to Participate in the Raymond James 45th Annual Institutional Investors Conference
-
Johnson & Johnson Reports Q4 and Full-Year 2023 Results
-
Biosense Webster Announces Regulatory Approval of VARIPULSE™ Pulsed Field Ablation (PFA) Platform in Japan
-
Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer
-
Johnson & Johnson Announces Quarterly Dividend for First Quarter 2024
-
Key Talc Lawyers: Planned “Prepack” J&J Bankruptcy is “Farce” and Improper Litigation Tactic
-
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
-
Johnson & Johnson to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
-
Publication in Bloomberg Law: ‘A Third J&J Bankruptcy Attempt Won’t Resolve Victims’ Talc Claims’ by Andy Birchfield
-
Johnson & Johnson Announces Key Drivers for Long-Term Competitive Growth at Enterprise Business Review
-
Johnson & Johnson Names Eugene A. Woods, Chief Executive Officer of Advocate Health, to its Board of Directors
-
Johnson & Johnson MedTech Acquires Laminar, Inc.
-
Talc Lawyer: Johnson & Johnson Settlements Undermine Bankruptcy Strategy, Serve as Acknowledgment That Baby Powder Contained Asbestos
-
Johnson & Johnson to Host Enterprise Business Review
-
Key Lawyer in Johnson & Johnson Talc Litigation Supports Call to Rethink Legal Strategies in Light of Failure of Texas Two-Step
-
New Biosense Webster QDOT MICRO™ Catheter Data Demonstrate Very High-Power, Short-Duration Ablations Improved Quality of Life and Reduced Healthcare Utilization for AFib Patients
-
Cancer Victims Support Sen. Richard Blumenthal in Urging Johnson & Johnson to Accept Responsibility
-
Johnson & Johnson Announces Departure of Ashley McEvoy, Tim Schmid Named Executive Vice President, Worldwide Chairman of MedTech
-
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2023
-
Johnson & Johnson Reports Q3 2023 Results
-
Press Release Biocartis Group NV: Disclosure of transparency notification
-
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
-
Johnson & Johnson Marks New Era as Global Healthcare Company With Updated Visual Identity
-
MustGrow and Janssen PMP, a division of Janssen Pharmaceutica NV, Announce Significant Project Expansion
-
Johnson & Johnson Announces Updated Financials and 2023 Guidance Following Completion of the Kenvue Separation
-
Johnson & Johnson Announces Final Results of Exchange Offer and Finalizes Separation of Kenvue Inc.
-
Johnson & Johnson to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
-
Kenvue Set to Join S&P 500; Advance Auto Parts to Join S&P SmallCap 600
-
Johnson & Johnson Announces Preliminary Results of Kenvue Inc. Exchange Offer
-
Johnson & Johnson Announces Final Exchange Ratio of 8.0324 in Split-Off of Kenvue Inc.
-
Kenvue Set to Join S&P 500
-
Johnson & Johnson to Participate in the 2023 Wells Fargo Securities Healthcare Conference
-
Biosense Webster Receives FDA Approval for Multiple Atrial Fibrillation Ablation Products to be Used in a Workflow Without Fluoroscopy
-
Nachawati Law Group Trial Lawyers Renew Commitment to Cancer Victims After Judge’s Rejection of Johnson & Johnson’s Proposed $8.9B Settlement
-
Biosense Webster Launches the OPTRELL™ Mapping Catheter with TRUEref™ Technology for Mapping of Complex Cardiac Arrhythmias
-
Kenvue To File Form S-4 Registration Statement in Connection with Johnson & Johnson Exchange Offer Announcement
-
Johnson & Johnson Launches Exchange Offer for Separation of Kenvue Inc.
-
Johnson & Johnson Reports Q2 2023 Results
-
Johnson & Johnson to Participate in the UBS MedTech, Tools and Genomics Summit
-
Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer
-
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
Back to JNJ Stock Lookup